Investigating the role of apolipoprotein C3 in heart disease for patients with type 1 diabetes
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
This study is looking at how the protein APOC3 in your blood might affect your chances of developing heart disease if you have type 1 diabetes, and it’s also exploring a new treatment that could help lower APOC3 levels to keep your heart healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11013961 on NIH RePORTER |
What this research studies
This research focuses on understanding how apolipoprotein C3 (APOC3) levels influence the risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. By analyzing blood samples from a large group of patients, the study aims to determine if higher levels of APOC3 in certain lipoproteins can predict the onset of heart disease. Additionally, the research explores the potential of using an antisense oligonucleotide therapy to lower APOC3 levels and reduce CVD risk. This approach is based on previous findings that suggest lowering APOC3 can prevent heart disease progression in diabetic models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes who are at risk for cardiovascular disease.
Not a fit: Patients without type 1 diabetes or those who do not have elevated cardiovascular disease risk may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of cardiovascular disease in patients with type 1 diabetes.
How similar studies have performed: Previous studies have shown promising results in reducing cardiovascular disease risk through similar approaches, indicating potential for success in this research.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Heinecke, Jay W — University of Washington
- Study coordinator: Heinecke, Jay W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.